Eli Lilly and Company has announced the availability of Zepbound (tirzepatide) 2.5 mg and 5 mg single-dose vials for self-pay patients with an on-label prescription. This expansion significantly increases the supply of Zepbound in response to high demand for the obesity treatment.
 
The single-dose vials offer substantial cost savings compared to other incretin (GLP-1) medicines for obesity, priced at a 50% or greater discount to the list price. This new option provides broader access to Zepbound for millions of adults with obesity, including those who are ineligible for the Zepbound savings card program, without employer coverage, or who need to self-pay outside of insurance.
 
“We are excited to share that the Zepbound single-dose vials are now here, further delivering on our promise to increase supply of Zepbound in the U.S.,” said Patrik Jonsson, executive vice president, and president of Lilly Cardiometabolic Health and Lilly USA. “These new vials not only help us meet the high demand for our obesity medicine, but also broaden access for patients seeking a safe and effective treatment option.”  
 
To ensure the integrity and safety of Zepbound, Lilly has established a new self-pay pharmacy component of LillyDirect where patients can purchase the vials with a valid, on-label prescription. This channel eliminates the risk of counterfeit or unsafe products and provides patients with access to genuine Lilly medicine. Additionally, Lilly has implemented a multi-step verification process to prevent the misuse of Zepbound for cosmetic weight loss, ensuring it is dispensed only to patients with a valid, on-label prescription.
 
Patients can also purchase ancillary supplies and access important patient-friendly instructional materials through the self-pay channel. The 2.5 mg Zepbound single-dose vial is priced at $399 for a four-week supply, while the 5 mg dose is $549, both significantly lower than the list price of other incretin medicines for obesity.
 
Zepbound has demonstrated impressive results in clinical studies, with patients achieving an average of 15% weight loss over 72 weeks when used in combination with a reduced calorie diet and increased physical activity. The medication’s unique dual-agonist mechanism targets the underlying causes of excess weight by reducing appetite and food intake. Zepbound is indicated for adults with obesity or those who are overweight and have weight-related medical problems.

More Lilly News